On July 24, President Trump signed four executive orders (EOs) designed to lower drug prices, adding new fuel to the already raging debate around prescription drug costs. The EOs focus on providing discounts for insulin and injectable epinephrine, allowing drug importation, eliminating rebates, and creating an index linking U.S. drug prices to pricing in other “reference” countries. The first three EOs have been released, while the fourth remains on hold, pending alternative proposals from drug manufacturers.
As we near the 2020 election, we can expect that the EOs are just the first step in a renewed focus on prescription drug pricing. With polls showing 70% of Americans consider lowering drug prices a top priority and lawmakers on both sides of the aisle vocal about wanting to reduce drug costs, we are likely to see increased efforts and attention on the issue in the days leading up to the election.
Will the EOs really drive change? How are healthcare stakeholders reacting? And what can we expect to see next? Find out at a new webinar from Manatt Health. Key topics that will be covered include:
- A detailed review of the four EOs, including their likely impact, open questions and implementation requirements
- The administrative actions that need to be taken for the EOs to go into effect
- An analysis of the challenges around moving forward, including uncertainty around the regulatory authority of the Department of Health & Human Services
- The industry’s reactions to the EOs and their anticipated effects on pricing in the real world
- The implications of the EOs for life sciences companies, providers, payers and patients
- The pricing policies and proposals we could see next as the election draws closer
Helen Pfister, Partner, Manatt Health
Ian Spatz, Senior Advisor, Manatt Health
Wendy Krasner, Senior Vice President of Regulatory Affairs, Pharmaceutical Care Management Association
Pam Traxel, Senior Vice President, Alliance Development and Philanthropy, American Cancer Society Cancer Action Network
Randy Burkholder, Vice President of Policy and Research, Pharmaceutical Research and Manufacturers of America (PhRMA)
Date and Time:
Thursday, August 27
This program has been approved for 1.0 CA MCLE General credit and 1.0 NY CLE Professional Practice credit (transitional and non-transitional).